{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:31:28Z","timestamp":1768278688601,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,19]]},"DOI":"10.7759\/cureus.97284","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T04:36:08Z","timestamp":1763613368000},"source":"Crossref","is-referenced-by-count":1,"title":["Alemtuzumab-Induced Resistant Thyroid Storm in a Patient With Graves\u2019 Disease Requiring Urgent Thyroidectomy: A Case Report"],"prefix":"10.7759","author":[{"given":"Shahzad","family":"Akbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samraiz","family":"Nafees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Haroon","family":"Riasat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Javeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Zamari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagannath","family":"Gopalappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Jayagopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles AJ","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al.. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012, 380:1829-39. 10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova E","year":"2015","unstructured":"Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015, 8:31-45. 10.1177\/1756285614563522","journal-title":"Ther Adv Neurol Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.928691","article-title":"Drug safety evaluation of alemtuzumab for multiple sclerosis","volume":"13","author":"Willis M","year":"2014","unstructured":"Willis M, Robertson NP. Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2014, 13:1115-24. 10.1517\/14740338.2014.928691","journal-title":"Expert Opin Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera C","year":"2017","unstructured":"Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2017, 13:871-9. 10.2147\/TCRM.S134398","journal-title":"Ther Clin Risk Manag"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2015.48","article-title":"Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management","volume":"42","author":"Mahzari M","year":"2015","unstructured":"Mahzari M, Arnaout A, Freedman MS. Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management. Can J Neurol Sci. 2015, 42:284-91. 10.1017\/cjn.2015.48","journal-title":"Can J Neurol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24570","article-title":"Thyroid storm in a patient with alemtuzumab-induced Graves\u2019 disease: a case report","volume":"14","author":"AlShehri S","year":"2022","unstructured":"AlShehri S, Alajmi S, Ekhzaimy A, Aldawas S, Alalwan M. Thyroid storm in a patient with alemtuzumab-induced Graves\u2019 disease: a case report. Cureus. 2022, 14:e24570. 10.7759\/cureus.24570","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7453-1","article-title":"Thyroid papillary carcinoma after alemtuzumab therapy for MS","volume":"261","author":"Ibitoye R","year":"2014","unstructured":"Ibitoye R, Wilkins A. Thyroid papillary carcinoma after alemtuzumab therapy for MS. J Neurol. 2014, 261:1828-9. 10.1007\/s00415-014-7453-1","journal-title":"J Neurol"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/S0889-8529(18)30165-8","article-title":"Life-threatening thyrotoxicosis. Thyroid storm","volume":"22","author":"Burch HB","year":"1993","unstructured":"Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993, 22:263-77.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad540","article-title":"Prevalence, risk factors, and clinical and biochemical characteristics of alemtuzumab-induced Graves disease","volume":"109","author":"Ueland G\u00c5","year":"2024","unstructured":"Ueland G\u00c5, Ueland HO, Stokland AM, et al.. Prevalence, risk factors, and clinical and biochemical characteristics of alemtuzumab-induced Graves disease. J Clin Endocrinol Metab. 2024, 109:344-50. 10.1210\/clinem\/dgad540","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-25-0007","article-title":"Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review","volume":"14","author":"Manso J","year":"2025","unstructured":"Manso J, Muller I, Mian C. Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review. Eur Thyroid J. 2025, 14:","journal-title":"Eur Thyroid J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061396","article-title":"The meaning of immune reconstitution after alemtuzumab therapy in multiple sclerosis","volume":"9","author":"Rolla S","year":"2020","unstructured":"Rolla S, Maglione A, De Mercanti SF, Clerico M. The meaning of immune reconstitution after alemtuzumab therapy in multiple sclerosis. Cells. 2020, 9:10.3390\/cells9061396","journal-title":"Cells"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09983-1","article-title":"Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo B","year":"2020","unstructured":"Steingo B, Al Malik Y, Bass AD, et al.. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020, 267:3343-53. 10.1007\/s00415-020-09983-1","journal-title":"J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09272-6","article-title":"Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis","volume":"266","author":"Frau J","year":"2019","unstructured":"Frau J, Coghe G, Lorefice L, Fenu G, Musu L, Cocco E. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. J Neurol. 2019, 266:1405-11. 10.1007\/s00415-019-09272-6","journal-title":"J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-020-01375-6","article-title":"Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis","volume":"121","author":"Zmira O","year":"2021","unstructured":"Zmira O, Halpern AI, Abraham L, Achiron A. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis. Acta Neurol Belg. 2021, 121:1513-8. 10.1007\/s13760-020-01375-6","journal-title":"Acta Neurol Belg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617722706","article-title":"Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world","volume":"10","author":"Ziemssen T","year":"2017","unstructured":"Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord. 2017, 10:343-59. 10.1177\/1756285617722706","journal-title":"Ther Adv Neurol Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211061335","article-title":"Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: benefit\/risk following review of trial and post-marketing data","volume":"28","author":"Coles AJ","year":"2022","unstructured":"Coles AJ, Jones JL, Vermersch P, et al.. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: benefit\/risk following review of trial and post-marketing data. Mult Scler. 2022, 28:842-6. 10.1177\/13524585211061335","journal-title":"Mult Scler"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-018-0883-2","article-title":"Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management","volume":"118","author":"Decallonne B","year":"2018","unstructured":"Decallonne B, Bartholom\u00e9 E, Delvaux V, et al.. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. Acta Neurol Belg. 2018, 118:153-9. 10.1007\/s13760-018-0883-2","journal-title":"Acta Neurol Belg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/360811-alemtuzumab-induced-resistant-thyroid-storm-in-a-patient-with-graves-disease-requiring-urgent-thyroidectomy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T04:36:09Z","timestamp":1763613369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/360811-alemtuzumab-induced-resistant-thyroid-storm-in-a-patient-with-graves-disease-requiring-urgent-thyroidectomy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.97284","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}